Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR) (Cardiotox)
|ClinicalTrials.gov Identifier: NCT00679874|
Recruitment Status : Terminated (No subjects indentifiable)
First Posted : May 19, 2008
Last Update Posted : October 4, 2011
University of Calgary
Information provided by (Responsible Party):
Oliver Strohm, University of Calgary
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
Nathan DM. Rosiglitazone and cardiotoxicity--weighing the evidence. N Engl J Med. 2007 Jul 5;357(1):64-6. Epub 2007 Jun 5.
McArthur HL, Chia S. Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med. 2007 Jul 5;357(1):94-5.
Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J. 2001 Jun;141(6):1007-13.